Systemic Sclerosis and Related Diseases
Systemic Sclerosis and Related Diseases is a research topic within Pathology and Forensic Medicine. Science Explorer counts 36k research works in it since 1950. 11.9% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the pathogenesis, clinical manifestations, and treatment of systemic sclerosis, with an emphasis on fibrosis, autoantibodies, pulmonary involvement, and the role of TGF-ß signaling. It also explores genetic markers, endothelial dysfunction, and various treatment approaches including immunosuppressive therapy for this complex autoimmune disease.
- Systemic Sclerosis
- Fibrosis
- Autoantibodies
- Pulmonary Involvement
- Treatment
- Raynaud's Phenomenon
- Genetic Markers
- Endothelial Dysfunction
- TGF-ß Signaling
- Immunosuppressive Therapy
- Research works
- 36k fractional, since 1950
- In the world top 10%
- 4.3k per year above
- Top-10% rate
- 11.9% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +32% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Systemic Sclerosis and Related Diseases research?
By volume, the United States and China publish the most (1.5k and 698 works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.5k works
- 2 China 698 works
- 3 Italy 507 works
- 4 United Kingdom 469 works
- 5 Japan 341 works
- 6 France 338 works
- 7 Germany 316 works
- 8 India 305 works
- 9 Spain 300 works
- 10 Türkiye 253 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Systemic Sclerosis and Related Diseases research?
By volume in 2022–2025, University College London publishes the most Systemic Sclerosis and Related Diseases research, followed by Chinese Academy of Medical Sciences & Peking Union Medical College and University of Michigan.
By volume, 2022–2025
- 1 University College LondonUnited Kingdom 33 works
- 2 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 29 works
- 3 University of MichiganUnited States 28 works
- 4 Johns Hopkins UniversityUnited States 26 works
- 5 Yale UniversityUnited States 25 works
- 6 InsermFrance 24 works
- 7 Sapienza University of RomeItaly 24 works
- 8 Association of Rheumatologists of RussiaRussia 23 works
- 9 University of PaduaItaly 22 works
- 10 Peking Union Medical College HospitalChina 22 works
Who are the leading researchers in Systemic Sclerosis and Related Diseases?
The most-cited researchers publishing on Systemic Sclerosis and Related Diseases include Mohammad Ali Sahraian and Sharareh Eskandarieh.
- 1 Mohammad Ali Sahraian Iran 4.6k citations
- 2 Sharareh Eskandarieh Iran 4.6k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Systemic Sclerosis and Related Diseases research done?
The largest centres of Systemic Sclerosis and Related Diseases research in 2022–2025 are London (United Kingdom), Beijing (China), Paris (France) and Tokyo (Japan). Among places with at least 20 works in it, it is an unusually large share of all research in Sousse and Brescia.
Largest cities, 2022–2025
Where it is the local speciality
- SousseTN · 20.9 works14×
- BresciaIT · 22.2 works13×
Location quotient: how much more of its research is in Systemic Sclerosis and Related Diseases than the world average.
Where is the best place to study Systemic Sclerosis and Related Diseases?
Among universities, judged by research, Vita-Salute San Raffaele University, University of Lübeck and Karolinska Institutet score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Vita-Salute San Raffaele UniversityItaly | 59.9 | 20.6% | 15.9× | 15 | +27.9% |
| 2 | University of LübeckGermany | 58.0 | 16.2% | 9.2× | 10 | +191.3% |
| 3 | Karolinska InstitutetSweden | 56.4 | 18.5% | 6.3× | 20 | +43.7% |
| 4 | University of BresciaItaly | 55.3 | 6.3% | 10.7× | 13 | +183.0% |
| 5 | University College LondonUnited Kingdom | 54.9 | 14.7% | 3.2× | 33 | +120.6% |
| 6 | Carol Davila University of Medicine and PharmacyRomania | 54.7 | 8.3% | 10.5× | 12 | +364.8% |
| 7 | University of FlorenceItaly | 51.1 | 21.2% | 5.4× | 21 | +28.1% |
| 8 | National and Kapodistrian University of AthensGreece | 51.1 | 20.0% | 4.3× | 16 | +149.3% |
| 9 | University of LeedsUnited Kingdom | 51.0 | 9.6% | 4.8× | 19 | +217.1% |
| 10 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 49.6 | 13.3% | 4.1× | 29 | +110.6% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Systemic Sclerosis and Related Diseases research growing?
Output in 2018–2022 was 32% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Systemic Sclerosis and Related Diseases.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.